Carlo Contreras, MD

home / authors / carlo-contreras-md

Articles

Carlo Contreras, MD, a surgical oncologist for Skin and Soft Tissue Cancers, a member of the Translational Therapeutics Program, medical director of Ambulatory Services at The Ohio State University Comprehensive Cancer Center (OSUCCC)–James, and an associate professor in the Division of Surgical Oncology at The Ohio State University

Dr. Contreras on the Use of Surgical Resection in Desmoplastic Melanoma

Carlo Contreras, MD
February 22nd 2023

Carlo Contreras, MD, discusses how continued investigations in desmoplastic melanoma could better inform the use of surgical resection in select patients.

Read More

Carlo Contreras, MD

Dr. Contreras on the Role of Neoadjuvant Pembrolizumab in Desmoplastic Melanoma

Carlo Contreras, MD
January 6th 2023

Carlo Contreras, MD, discusses the role of neoadjuvant pembrolizumab for the treatment of patients with desmoplastic melanoma.

Read More

Carlo Contreras, MD, surgical oncologist, The Ohio State University Comprehensive Cancer Center (OSUCCC)–James

Dr. Contreras on Neoadjuvant Therapies in Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Carlo Contreras, MD
December 19th 2022

Carlo Contreras, MD, discusses areas of planned and ongoing research with neoadjuvant therapies in basal cell carcinoma and cutaneous squamous cell carcinoma.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data